ABEO: ZEVASKYN's launch accelerates with expanding access, strong coverage, and promising patient outcomes
ZEVASKYN's U.S. launch is progressing with expanding treatment centers, robust reimbursement, and positive early patient outcomes. The addressable market exceeds $4 billion, with steady growth expected as more centers gain experience. Additional revenue streams from partnered programs and a new pro…